Maritech fucoidan research part of $270m Australian R&D initiative

Current estimates suggest Australia’s marine bioproducts are on track to reach $1bn turnover by 2030

Marinova has joined the Marine Bioproducts Cooperative Research Centre (MB-CRC), a $270m consortium of 68 partners led by Flinders University. It’s aimed to fast-track the growth of Australia’s marine bio-industries to meet global demand for safe and sustainable products including plant-based proteins, nutraceuticals, omega 3 oils, cosmetics, agrochemicals, bioplastics and more.

“Marinova is proud to be a part of this innovative consortium of industry, government and academic partners,” said company CEO & MD, Mr Paul Garrott. “Australia is increasingly being recognized as a world leader in the research and manufacture of high value marine bioproducts. The collaborations that will result from the MB-CRC will drive innovative new research projects and further enhance this country’s global reputation. We look forward to working alongside partners who not only share our passion for improved health outcomes but also our vision for an expansive - and sustainable - marine bioproducts sector in Australia. The future opportunities for superior algal-derived products here are huge.”

“Marinova’s involvement in the MB-CRC will fast-track a number of very significant research projects that we have planned for our unique fucoidan extracts,” continued Mr Garrott.

Maritech fucoidan is a high purity, organic fucoidan with global regulatory acceptance, the company claims. It expects commercial opportunities to emerge from expanding the research program, particularly in the areas of immune modulation, viral inhibition, gut & digestive health, anti-cancer, anti-inflammation and anti-ageing.

Companies